Q1 Earnings Estimate for AVTX Issued By HC Wainwright

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Avalo Therapeutics in a report issued on Thursday, March 20th. HC Wainwright analyst E. White forecasts that the company will post earnings per share of ($1.06) for the quarter. HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Avalo Therapeutics' current full-year earnings is ($19.07) per share. HC Wainwright also issued estimates for Avalo Therapeutics' Q2 2025 earnings at ($1.09) EPS and Q3 2025 earnings at ($1.13) EPS.

AVTX has been the subject of several other reports. Stifel Nicolaus started coverage on shares of Avalo Therapeutics in a report on Tuesday. They issued a "buy" rating and a $36.00 target price for the company. Piper Sandler began coverage on Avalo Therapeutics in a research note on Friday, February 28th. They issued an "overweight" rating and a $48.00 price target for the company. Wedbush reaffirmed an "outperform" rating and set a $18.00 price target on shares of Avalo Therapeutics in a report on Thursday, March 20th. Jefferies Financial Group initiated coverage on shares of Avalo Therapeutics in a research report on Tuesday. They set a "buy" rating and a $23.00 price objective on the stock. Finally, BTIG Research initiated coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They issued a "buy" rating and a $40.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $33.00.

Remove Ads

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX traded up $0.37 on Monday, hitting $8.73. 83,023 shares of the company traded hands, compared to its average volume of 211,121. The stock has a 50 day simple moving average of $7.55 and a 200-day simple moving average of $9.13. Avalo Therapeutics has a 52 week low of $4.60 and a 52 week high of $34.46.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. BVF Inc. IL increased its stake in shares of Avalo Therapeutics by 7.2% in the 4th quarter. BVF Inc. IL now owns 1,036,679 shares of the company's stock worth $7,703,000 after purchasing an additional 69,679 shares in the last quarter. Ikarian Capital LLC increased its position in Avalo Therapeutics by 1,673.0% in the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company's stock worth $9,218,000 after buying an additional 915,629 shares in the last quarter. RA Capital Management L.P. bought a new position in shares of Avalo Therapeutics in the third quarter worth about $9,186,000. Affinity Asset Advisors LLC raised its stake in shares of Avalo Therapeutics by 1,123.9% in the fourth quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company's stock worth $4,092,000 after buying an additional 505,765 shares during the period. Finally, Velan Capital Investment Management LP purchased a new position in shares of Avalo Therapeutics during the 4th quarter valued at about $817,000. 87.06% of the stock is currently owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.